CA2488861A1 - Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema - Google Patents

Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema Download PDF

Info

Publication number
CA2488861A1
CA2488861A1 CA002488861A CA2488861A CA2488861A1 CA 2488861 A1 CA2488861 A1 CA 2488861A1 CA 002488861 A CA002488861 A CA 002488861A CA 2488861 A CA2488861 A CA 2488861A CA 2488861 A1 CA2488861 A1 CA 2488861A1
Authority
CA
Canada
Prior art keywords
treatment
hydroxy
group
production
iloprost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002488861A
Other languages
English (en)
French (fr)
Inventor
Cornelia Norden
Nicolas Aigner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2488861A1 publication Critical patent/CA2488861A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002488861A 2002-06-06 2003-06-05 Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema Abandoned CA2488861A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10225551.2 2002-06-06
DE10225551A DE10225551A1 (de) 2002-06-06 2002-06-06 Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind
PCT/EP2003/005990 WO2003103681A2 (de) 2002-06-06 2003-06-05 Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziert sind

Publications (1)

Publication Number Publication Date
CA2488861A1 true CA2488861A1 (en) 2003-12-18

Family

ID=29594336

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002488861A Abandoned CA2488861A1 (en) 2002-06-06 2003-06-05 Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema

Country Status (9)

Country Link
EP (1) EP1515728A2 (de)
JP (1) JP2005536476A (de)
KR (1) KR20050007591A (de)
CN (1) CN1658882A (de)
AU (1) AU2003236715A1 (de)
CA (1) CA2488861A1 (de)
DE (1) DE10225551A1 (de)
WO (1) WO2003103681A2 (de)
ZA (1) ZA200500097B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092343A2 (en) * 2006-02-03 2007-08-16 Scidose Llc Novel epoprostenol formulation and method of making thereof
TWI520740B (zh) * 2011-02-02 2016-02-11 模範健康科技私人企業有限公司 利用多硫酸化多醣之骨髓水腫（水腫）的治療
EP3675909B1 (de) * 2017-08-31 2023-10-18 Charité Universitätsmedizin Berlin Immunmodulation zur verhinderung der schlechten heilung von muskel-skelett-läsionen bei beeinträchtigten patienten

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
EP0686036B1 (de) * 1992-08-07 1997-03-12 Schering Aktiengesellschaft Verwendung von prostanderivaten zur herstellung eines arzneimittels zur behandlung der chronischen polyarthritis
WO1999013880A1 (fr) * 1997-09-16 1999-03-25 Toray Industries, Inc. Inhibiteur de la production de chemokine c-c
AU2002212996A1 (en) * 2000-09-28 2002-04-08 Non-Invasive Monitoring Systems, Inc. External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention

Also Published As

Publication number Publication date
DE10225551A1 (de) 2003-12-24
EP1515728A2 (de) 2005-03-23
AU2003236715A1 (en) 2003-12-22
ZA200500097B (en) 2006-06-28
WO2003103681A3 (de) 2004-03-25
WO2003103681A2 (de) 2003-12-18
CN1658882A (zh) 2005-08-24
KR20050007591A (ko) 2005-01-19
JP2005536476A (ja) 2005-12-02

Similar Documents

Publication Publication Date Title
RU2166940C2 (ru) Способ уменьшения потерь костной ткани, способ лечения остеопороза и применение соединения
US4666897A (en) Inhibition of mammalian collagenolytic enzymes by tetracyclines
JP4741183B2 (ja) 骨関節症を治療するための、ヒアルロン酸ナトリウムとコンドロイチン硫酸との混合物の使用
JP3623962B2 (ja) ヒドロキソコバラミンの鼻中投与用医薬組成物
US5324746A (en) Method of treating damaged mucosal and epithelial tissues with misoprostol
JPH09504543A (ja) 白内障の予防法及び予防手段
CA2592086C (en) Mixture of a vanilloid receptor agonist and a substance inhibiting nerve regeneration, use thereof for producing a painkiller, and method for applying said painkiller
JP2004532868A5 (de)
CA2594202A1 (en) Use of resiniferatoxin (rtx) for producing an agent for treating joint pains and method for applying said agent
JP5080983B2 (ja) バニロイド受容体アゴニストをグリコースアミノグリカンまたはプロテオグリカンとともに関節痛治療のための薬剤の製造に用いることおよび前記薬剤の適用方法
GB2330307A (en) EP4 Receptor antagonists as bone resorption inhibitors
US20050101673A1 (en) Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas
CA2488861A1 (en) Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema
US4185108A (en) Antiosteoporotic agents
US4125621A (en) Antiosteoporotic agents
EP1080728A1 (de) Prostaglandin ep4 rezeptor agonist und behandlungsverfahren
Herbai TREATMENT OF PROGRESSIVE SYSTEMIC SCLEROSIS WITH A SYNTHETIC WEAK ESTROGEN: CYCLOFENIL (SEXOVID®) Report of a Case
NZ308935A (en) Use of Alendronate for the prevention of osteoporosis
CA2219354A1 (en) Prevention of tooth loss by the administration of alendronate or its salts
Stewart et al. Acquired anterior open bite and facial arthromyalgia: possible aetiology
WO2004009117A1 (ja) Ｅｐ２アゴニストを有効成分とする子宮収縮抑制剤
JPH0753388A (ja) 骨代謝改善剤
JP2004123558A (ja) 片頭痛の予防、治療剤
WO1995028933A1 (en) Use of arylpiperazine derivatives for the treatment of parkinson's disease and psychosis
US6897239B1 (en) Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women

Legal Events

Date Code Title Description
FZDE Discontinued